Rigel PharmaceuticalsRIGL
About: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Employees: 164
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
3,662% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $34K
300% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 10
126% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 19
32% more funds holding
Funds holding: 92 [Q3] → 121 (+29) [Q4]
5% more capital invested
Capital invested by funds: $193M [Q3] → $203M (+$9.97M) [Q4]
0.8% more ownership
Funds ownership: 67.65% [Q3] → 68.45% (+0.8%) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Citigroup Yigal Nochomovitz 20% 1-year accuracy 8 / 41 met price target | 181%upside $55 | Buy Maintained | 6 Mar 2025 |
B. Riley Securities Kalpit Patel 40% 1-year accuracy 4 / 10 met price target | 23%upside $24 | Neutral Maintained | 5 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 81 / 415 met price target | 191%upside $57 | Buy Reiterated | 5 Mar 2025 |
Financial journalist opinion
Based on 5 articles about RIGL published over the past 30 days
